Welcome to the Center for Targeted Therapeutics and Translational Nanomedicine

Congratulations to Vladimir Muzykantov, MD, PhD, on his Founders Professorship of Nanoparticle Research!

Celebration on January 16th, with Profs. E. John Wherry, Vlad Muzykantov, Drew Weissman, and Jonathan A. Epstein 

Muzykantov lab members and alumni

Missed the 2023 CT3N Symposium? Talks are now available here to stream. 


Congratulations to long-time CT3N member Drew Weissman on being awarded the 2023 Nobel Prize in Physiology or Medicine (shared with Katalin Karikó)

CT3N is a joint interdisciplinary venture between the Perelman School of Medicine (PSOM) and the School of Engineering and Applied Science (SEAS), with the mission to facilitate and accelerate translational research in targeted therapeutics and nanomedicines by bringing together the many leading laboratories active in these areas at the University of Pennsylvania, CHOP and surrounding academic institutions.  Research areas being pursued by CT3N faculty include design of biomaterials and carriers for drug delivery, identification of molecular targets for cell-specific delivery, studies of targeting, binding, sub-cellular trafficking and metabolism of targeted drugs. These studies use modern strategies of nanotechnology, bioconjugation and recombinant fusion proteins, phage display libraries, cellular grafting, monoclonal antibodies, bioengineering, computational modeling, and diverse imaging modalities. The efficacy and safety of novel therapeutic approaches are evaluated in a wide range of cell culture and animal models.

Learn more about CT3